EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib

Ting Hon Stanford Li iD, Yin Kwan Jeannie Chik, Ka Yan Ng, Wai Shan Wong

Journal of Clinical Laboratory Analysis · 2024

DOI: 10.1002/jcla.25089 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Clinical Laboratory Analysis, 2024. Verfasst von Ting Hon Stanford Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong. Hauptthemen laut MEDLINE: Piperidines, Carbazoles, Erythrocytes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alectinib is a second‐generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK‐mutated non‐small‐cell lung cancer. Recently, the association between alectinib and red cell morphological abnormalities has been reported in a few case series. This retrospective observational study aims to determine the frequency of occurrence of acanthocytosis in patients taking alectinib and to evaluate the red cell indices, biochemical markers of haemolysis and eosin‐5‐maleimide (EMA) binding assay results in patients receiving alectinib.

Methods

Patients who were on alectinib and had a complete blood count test performed in Queen Elizabeth Hospital Haematology Laboratory between 1 May 2021 and 31 August 2021 were included in the study. Haematological investigations that had been performed before and after the commencement of alectinib were reviewed.

Results

Fifty patients receiving alectinib were evaluated in this analysis. One hundred per cent of patients showed 3+ acanthocytes on the peripheral blood smears. Compared with the test results before starting alectinib, the post‐alectinib blood tests showed a significantly lower haemoglobin concentration, red blood cell count and haematocrit; and a significantly higher mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration and red cell distribution width. All the tested patients showed a marked reduction in EMA mean channel fluorescence compared with normal control.

Conclusion

Our cohort revealed that alectinib caused significant acanthocytosis in all patients. Alectinib was also associated with changes in red cell indices and biochemical markers of haemolysis, compatible with a spherocytic and anisopoikilocytic morphology with haemolysis. Patients on alectinib had reduced EMA binding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesCarbazolesErythrocytesHumansMaleFemaleMiddle AgedRetrospective StudiesAgedErythrocyte IndicesAdultProtein Kinase InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsAged, 80 and overHematologic Tests

Stichwörter der Autor:innen

acanthocytosisalectinibalectinib‐induced haemolysisanaemiadrug‐induced haemolysis

Substanzen

alectinibPiperidinesCarbazolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong.
  • Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.

ORCID-Profile: Ting Hon Stanford Li

Zitieren

APA

Li, T. H. S., Chik, Y. K. J., Ng, K. Y., & Wong, W. S. (2024). Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.25089

Vancouver

Li THS, Chik YKJ, Ng KY, Wong WS. Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib. Journal of Clinical Laboratory Analysis. 2024. doi:10.1002/jcla.25089

BibTeX
@article{Li2024,
  author = {Li, Ting Hon Stanford and Chik, Yin Kwan Jeannie and Ng, Ka Yan and Wong, Wai Shan},
  title = {Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2024},
  doi = {10.1002/jcla.25089}
}
Kostenlos starten →